{
    "nctId": "NCT04657341",
    "briefTitle": "Sonazoid Contrast-enhanced Ultrasound in Assessing Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer Patients.",
    "officialTitle": "Sonazoid Contrast-enhanced Ultrasound in Assessing Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer Patients.",
    "overallStatus": "UNKNOWN",
    "conditions": "Ultrasound",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1012,
    "primaryOutcomeMeasure": "Sonazoid contrast-enhanced ultrasound in assessing effectiveness of neoadjuvant chemotherapy in breast cancer patients.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* (1) Refer to the guidelines and specifications for diagnosis and treatment of breast cancer, and it is clearly identified as breast cancer by pathological biopsy.\n* (2) Plan to implement NAC therapy;\n* (3) All patients and their family members signed informed consent forms, which were approved by the hospital medical Ethics Committee\n\nExclusion Criteria:\n\n* (1) Those who are known to be allergic to ultrasound contrast agents;\n* (2)The subject has a history of allergy to eggs or egg products (i.e. skin rash, dyspnea, swelling of the mouth or throat, hypotension or shock, etc.)\n* (3) Intolerance to neoadjuvant chemotherapy;\n* (4) Poor compliance with chemotherapy treatment;\n* (5) Patients who cannot receive contrast agent MRI examination\n* (6) Arteriovenous (left and right) shunt patients in the heart and lungs;\n* (7) Mental disorders or mental disorders;\n* (8)Patients with serious heart disease or lung disease;\n* (9)Pet-pregnant, possibly pregnant or lactating;\n* (10)In addition, the researcher or the researcher thinks that the patient is not suitable to participate in this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}